COMPREHENSIVE ANTIBIOGRAM for McMasterall clinical areas

January 1 to June 30, 2006

% SUSCEPTIBLE

# Isolates / Amikacin / Ampicillin / Azithromycin / Beta lactamase / Cefazolin / Cefotaxime / Ceftazidime / Ciprofloxacin / Clindamycin / Gentamicin
synergy* / Levofloxacin / Meropenem / Oxacillin / Penicillin-G / Piperacillin / Piperacillin
/tazobac / Streptomycin
synergy* / Tetracycline / Tobramycin / Trimethprim/Sulfa / Vancomycin
GRAM POSITIVE
Enterococcus faecalis / 50 / 100 / 60 / 100* / 98 / 100 / 28 / 100
Enterococcus faecium / 10 / 20 / 0 / 100* / 10 / 100 / 50 / 100
Enterococcus group D / 136 / 100 / 60 / 100* / 97 / 99 / 26 / 100
Staphylococcus aureus (includes MRSA) / 325 / 16 / 89 / 81 / 61 / 97 / 89 / 97 / 98 / 100

MRSA

/ 33 / 0 / 0 / 3 / 12 / 91 / 0 / 94 / 94 / 100

Streptococcus pneumoniae

/ 29 / 100 / 88 / 95 / 97 / 81 / 88 / 88 / 100
GRAM NEGATIVE
Escherichiae coli / 516 / 99 / 56 / 87 / 97 / 97 / 83 / 91 / 100 / 59 / 98 / 92 / 77
Klebsiella pneumoniae / 104 / 98 / 0 / 83 / 93 / 93 / 93 / 94 / 100 / 86 / 93 / 94 / 87
Pseudomonas aeruginosa / 112 / 94 / 88 / 76 / 85 / 96 / 96 / 95 / 94
MR Pseudo. aeruginosa / 33 / 30 / 24 / 3 / 3 / 45 / 39 / 45 / 6

* Percentage of organisms with synergistic bactericidal activity with gentamicin/streptomycin when combined with penicillin/vancomycin.

++ These organisms may produce inducible ß-lactams Use of ß-lactams may result in clinical failure despite in vitro susceptibility.